Shanghai-based Oricell Therapeutics announced the closing of a pre-IPO financing round in excess of $110 million, the proceeds of which will be used to accelerate the company’s global expansion and clinical development, while paving the way to upcoming capital market milestones.
The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma. Having successfully navigated investigator-initiated trials (IIT) and a registrational phase 1 study, the program is now gearing up for pivotal trials. Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-gen modalities, including secreted, rapid-production, and in vivo CAR-T programs.
By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo(Fast) rapid CMC manufacturing expertise, the company has built a differentiated CAR-T portfolio.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!